References
- Applewhaite F, Ginsberg V, Gerena J, et al. A very frequent red cell antigen, Ata. Vox Sang 1967;13:444–5.
- Gellerman MM, McCreary J, Yedinak E, Stroup M. Six additional examples of anti-Ata. Transfusion 1973;13:225–30.
- Frank S, Schmidt RP, Baugh M. Three new antibodies to high-incidence antigenic determinants (anti-El, anti-Dp, and anti-So). Transfusion 1970;10:254–7.
- Brown A, Harris P, Daniels GL, Frank S, Moore BPL, Berger R. Ata (August) and El (Eldr) are synonymous. Transfusion 1983;44:123–5.
- Daniels G, Bailif BA, Helias V, et al. Lack of nucleoside transporter ENT1 results in the Augustine-null blood type and ectopic mineralization. Blood 2015;125:3651–4.
- Storry JR, Castilho L, Chen Q, et al. International Society of Blood Transfusion Working Party on Red Cell Immunogenetics and Terminology: Report of the Seoul and London meetings. ISBT Sci Ser 2016;11:118–22.
- Winkler MM, Hamilton JR. Previously tested donors eliminated to determine rare phenotype frequencies [abstract]. In: Proc 21st Joint Congr Int Soc Blood Transfus Am Ass Blood Banks 1990:158.
- Vengelen-Tyler V. Efficient use of scarce sera in screening thousands of donors [abstract]. Transfusion 1985;25:476.
- Sweeney JD, Holme S, McCall L, et al. At(a–) phenotype: description of a family and reduced survival of At(a+) red cells in a proposita with anti-Ata. Transfusion 1995:35:63–7.
- Ramsey G, Sherman LA, Zimmer AM, et al. Clinical significance of anti-Ata. Vox Sang 1995;69:135–7.
- Cash K, Brown T, Sausais L, et al. Severe delayed hemolytic transfusion reaction secondary to anti-Ata. Transfusion 1999; 39:834–7.
- Daniels G. Human blood groups. 3rd ed. Oxford, UK: Wiley-Blackwell, 2013.
- Reid ME, Lomas-Francis C, Olsson ML. The blood group antigen factsbook. 3rd ed. London, UK: Elsevier, 2012.
- Arndt PA, Garratty G. A retrospective analysis of the value of monocyte monolayer assay results for predicting clinical significance of blood group alloantibodies. Transfusion 2004;44:1273–81.
- Culver PL, Brubaker DB, Sheldon RE, et al. Anti-Ata causing mild hemolytic disease of the newborn. Transfusion 1987;27:468–70.
- McBean R, Liew Y-W, Wilson B, et al. Genotyping confirms inheritance of the rare At(a–) type in a case of haemolytic disease of the newborn. J Pathol Clin Res 2016;2:53–5.
- Griffiths M, Beaumont N, Yao SY, et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 1997;3: 89–93.
- Young JD, Yao SY, Sun L, et al. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008;38:995–1021.
- Grenz A, Bauerle JD, Dalton JH, et al. Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest 2012;122:693–710.
- Mediero A, Cronstein BN. Adenosine and bone metabolism. Trends Endocrinol Metab 2013;24:290–300.
- Warraich S, Bone DB, Quinonez D, et al. Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans. J Bone Miner Res 2013;28:1135–49.
- Hinton DJ, McGee-Lawrence ME, Lee MR, et al. Aberrant bone density in aging mice lacking the adenosine transporter ENT1. PLoS One 2014;9:e88818.
- Endres CJ, Moss AM, Ke B, et al. The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or Ent1–/– mouse erythrocytes. J Pharmacol Exp Ther 2009;329:387–98.
- Ibarra KD, Pfeiffer JK. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J Virol 2009;83:4538–47.